Merck & Co licenses Isis drug

Published: 29-Jun-2001


Isi Pharmaceuticals has licensed its preclinical Type II diabetes antisense drug candidate ISIS 113715 to Merck & Co. Preclinical data demonstrate activity in animal models of Type II diabetes.

You may also like